Cipla Q4 Earnings: Profit Slumps 55% to ₹555 Crore on Charges
Cipla's investors braced for turbulence as the pharma major disclosed Q4 FY 2025-26 results, revealing a 54.6% nosedive in net profit to ₹554.64 crore from ₹1,221.84 crore year-ago. A key culprit:...
Cipla's investors braced for turbulence as the pharma major disclosed Q4 FY 2025-26 results, revealing a 54.6% nosedive in net profit to ₹554.64 crore from ₹1,221.84 crore year-ago. A key culprit: impairment charges on associate firms amid turbulent business conditions. Operational revenue edged down 2.8% to ₹6,541.20 crore versus ₹6,729.69 crore previously. EBITDA cratered 38% to ₹955 crore, squeezing margins from 22.8% to 14.6%. In its filing, Cipla explained the ₹42.02 crore impairment for the period ended March 31, 2026, stemmed from changing market dynamics. Adjusted for this, EBITDA improves to ₹997 crore (15.2% margin), offering a silver lining. On a positive note, the board greenlit a ₹13 per share final dividend for FY 2025-26, to be disbursed post-AGM within 30 days. Shareholders eligible as of the June 5, 2026 record date. The market shrugged off the headline profit fall, propelling shares up 3.5% to ₹1,338.10 on NSE around 2:40 PM. This upbeat response underscores faith in Cipla's fundamentals: a powerhouse in respiratory, cardiovascular, and anti-infective segments, bolstered by innovation pipelines. As Cipla navigates sector-specific risks like US FDA inspections and patent cliffs, its Q4 performance highlights vulnerability to one-offs but reaffirms operational steadiness. Stakeholders anticipate management's guidance in the earnings call for clarity on growth drivers.